A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies

Haplo-HSCT has been used when HLA-matched siblings are not available. Conditioning regimens aim to reduce tumor burden prior to HSCT and provide sufficient immunoablation. We report the outcome of haplo-HSCT in 63 consecutive patients from 2/2013 to 12/2015 (19 females/44 males) with high-risk or re...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ting, Lin, Qiaoxian, Ren, Jinhua, Chen, Ping, Yuan, Xiaohong, Luo, Xiaofeng, Liu, Tingbo, Zheng, Jing, Zheng, Zhihong, Zheng, Xiaoyun, Chen, Xinji, Zhang, Langhui, Zheng, Hao, Chen, Zaisheng, Hua, Xueling, Le, Shaohua, Li, Jian, Chen, Zhizhe, Hu, Jianda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346676/
https://www.ncbi.nlm.nih.gov/pubmed/27705929
http://dx.doi.org/10.18632/oncotarget.12383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346676/
https://www.ncbi.nlm.nih.gov/pubmed/27705929
http://dx.doi.org/10.18632/oncotarget.12383

Ejemplares similares